AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15905296 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus flutamide (62.5 mg/day)
Number of subjects: 118
Study 15905296 — intervention group
Group type: COMPARATOR
Intervention: Oral contraception (OC) monotherapy
Number of subjects: 118
Study 15905296 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraception plus flutamide-metformin
Number of subjects: 118
Study 12569142 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-cis-retinoic acid (100 mg daily for 3 months)
Number of subjects: 226
Study 12569142 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (1 mg/kg) + alpha-tocopherol (1200 IU) for 3 months
Number of subjects: 226
Study 12569142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 10554530 — intervention group
Group type: COMPARATOR
Intervention: Amifostine
Number of subjects: 30
Study 10554530 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 30
Study 8736145 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's dementia (AD)
Number of subjects: 29
Study 8736145 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD)
Number of subjects: 29
Study 8736145 — intervention group
Group type: COMPARATOR
Intervention: Control group (chronic depression)
Number of subjects: 29
Study 1759096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of tincture of belladonna (0.01 mg/kg weight of atropine)
Number of subjects: 20
Study 1759096 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup containing no belladonna
Number of subjects: 20
Study 1759096 — intervention group
Group type: COMPARATOR
Intervention: Both belladonna and placebo
Number of subjects: 20
Study 7137431 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental consent regulation for neonatal screening
Number of subjects: 0
Study 31773209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherry flavored e-liquid (24 mg/ml)
Number of subjects: 18
Study 31773209 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanilla flavored e-liquid (24 mg/ml)
Number of subjects: 18
Study 31773209 — intervention group
Group type: EXPERIMENTAL
Intervention: All flavored e-liquids
Number of subjects: 18
Study 31773209 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol flavored e-liquid (24 mg/ml)
Number of subjects: 18
Study 30684522 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (unspecific MR/GR agonist)
Number of subjects: 80
Study 30684522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (specific MR agonist)
Number of subjects: 80
Study 28760368 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACG)
Number of subjects: 60
Study 28760368 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (NACG)
Number of subjects: 60
Study 25184801 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid AFO
Number of subjects: 10
Study 25184801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic AFO
Number of subjects: 10
Study 25184801 — intervention group
Group type: COMPARATOR
Intervention: Without AFO
Number of subjects: 10
Study 23297009 — intervention group
Group type: EXPERIMENTAL
Intervention: Attributional bias task during fMRI scanning
Number of subjects: 71
Study 22050610 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the external fascia (group A)
Number of subjects: 162
Study 22050610 — intervention group
Group type: COMPARATOR
Intervention: No closure of the external fascia (group B)
Number of subjects: 162
Study 19919718 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic physical exercise (walking 10 minutes, aerobic exercise 30 minutes, stretching 10 minutes, relaxation exercise 10 minutes, three sessions per week)
Number of subjects: 64
Study 19919718 — intervention group
Group type: COMPARATOR
Intervention: Activities of daily living (bathing, dressing, eating, walking) without counselling from a physical therapist
Number of subjects: 64
Study 16619524 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason pattern 3 (G3) tumors
Number of subjects: 17
Study 16619524 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason pattern 4 (G4) tumors
Number of subjects: 17
Study 16619524 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Gleason patterns 3 and 4
Number of subjects: 17
Study 16619524 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Gleason grades within one cancer
Number of subjects: 17
Study 15354946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosulepin
Number of subjects: 27
Study 15354946 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 11139961 — intervention group
Group type: EXPERIMENTAL
Intervention: dofetilide (500 micrograms bid)
Number of subjects: 57
Study 11139961 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol (160 mg bid)
Number of subjects: 57
Study 9052343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 2 mg/kg over 30 minutes, followed by oral propafenone 150 mg 3 times daily
Number of subjects: 136
Study 9052343 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 136
Study 9052343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 150 mg 3 times daily
Number of subjects: 136
Study 9052343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 136
Study 8111802 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg torsemide
Number of subjects: 70
Study 8111802 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg torsemide
Number of subjects: 70
Study 8111802 — intervention group
Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 70
Study 2427858 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol for 3 weeks, then increased to 300 mg or added diuretic for another 3 weeks
Number of subjects: 2694
Study 2427858 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg celiprolol
Number of subjects: 2694
Study 2427858 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic added to treatment
Number of subjects: 2694
Study 2427858 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol treatment
Number of subjects: 2694
Study 2427858 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol administered for up to 6 weeks
Number of subjects: 2694
Study 31482201 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement pathway inhibition
Number of subjects: 0
Study 31482201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31606288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-treatment MRI showing complete response (mCR)
Number of subjects: 519
Study 31606288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-treatment MRI showing partial response (mPR)
Number of subjects: 519
Study 31606288 — intervention group
Group type: COMPARATOR
Intervention: Stable/progressive disease (SD/PD)
Number of subjects: 519
Study 29946106 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep rTMS (H1 coil, 6012 pulses, 18 Hz, 120% of resting motor threshold)
Number of subjects: 52
Study 29946106 — intervention group
Group type: COMPARATOR
Intervention: Sham deep rTMS
Number of subjects: 52
Study 29946106 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep rTMS
Number of subjects: 52
Study 27496103 — intervention group
Group type: EXPERIMENTAL
Intervention: kJ labelling alone
Number of subjects: 713
Study 27496103 — intervention group
Group type: EXPERIMENTAL
Intervention: kJ labelling with social marketing campaign
Number of subjects: 713
Study 27496103 — intervention group
Group type: COMPARATOR
Intervention: kJ labelling
Number of subjects: 713
Study 24075889 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide (290 μg, oral, once daily for 12 weeks)
Number of subjects: 1602
Study 24075889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602
Study 24075889 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide
Number of subjects: 1602
Study 22858390 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 1001
Study 22858390 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 1001
Study 20392890 — intervention group
Group type: EXPERIMENTAL
Intervention: Red tomato paste (200 g/d providing 16 mg lycopene)
Number of subjects: 30
Study 20392890 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified lycopene (16 mg/d)
Number of subjects: 30
Study 20392890 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow tomato paste (200 g/d providing 0 mg lycopene)
Number of subjects: 30
Study 20392890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18923312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg intrathecal morphine (M-group)
Number of subjects: 46
Study 18923312 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (P-group)
Number of subjects: 46
Study 16443789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 89
Study 12808527 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based multidisciplinary cognitive behavioral therapy
Number of subjects: 113
Study 12808527 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy cognitive behavioral therapy
Number of subjects: 113
Study 11304027 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) infusion (0.5 microg/kg per min for 20 min)
Number of subjects: 16
Study 11304027 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study 11304027 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) infusion
Number of subjects: 16
Study 8970355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 10
Study 8970355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (5 micrograms/kg/min)
Number of subjects: 10
Study 1365868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 supplementation (20 mg pyridoxine HCL daily for 3 months)
Number of subjects: 38
Study 1365868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6532126 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (4 X 25 mg, orally)
Number of subjects: 0
Study 6532126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate (4 X 250 mg, orally)
Number of subjects: 0
Study 6532126 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg) plus sodium salicylate (250 mg) (Pelsonin, 4 X 1 capsules)
Number of subjects: 0
Study 6532126 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline gastric bleeding)
Number of subjects: 0
Study 30439945 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO dose pole for praziquantel (PZQ) dosing
Number of subjects: 9827
Study 30439945 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dose pole for praziquantel (PZQ) dosing
Number of subjects: 9827
Study 27133379 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPT9 gene methylation assay
Number of subjects: 1031
Study 27133379 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPT9 gene methylation assay combined with carcinoembryonic antigen
Number of subjects: 1031
Study 27133379 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPT9 gene methylation assay combined with fecal immunochemical test
Number of subjects: 1031
Study 27133379 — intervention group
Group type: COMPARATOR
Intervention: Epi proColon 2.0
Number of subjects: 1031
Study 25643511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week anti-HP therapy plus 90-day oral iron
Number of subjects: 60
Study 25643511 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week anti-HP therapy alone
Number of subjects: 60
Study 25643511 — intervention group
Group type: COMPARATOR
Intervention: 90-day oral iron alone
Number of subjects: 60
Study 23515583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron add-on to risperidone
Number of subjects: 40
Study 23515583 — intervention group
Group type: COMPARATOR
Intervention: Placebo add-on to risperidone
Number of subjects: 40
Study 19825906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 22
Study 19825906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19006730 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-IOL
Number of subjects: 495
Study 19006730 — intervention group
Group type: COMPARATOR
Intervention: CM-IOL
Number of subjects: 495
Study 15689407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Number of subjects: 395
Study 15689407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 12182253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate 200 mg
Number of subjects: 498
Study 12182253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen arginate 400 mg
Number of subjects: 498
Study 12182253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 498
Study 12182253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 498
Study 12182253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 10367716 — intervention group
Group type: COMPARATOR
Intervention: Heat-induced dehydration (D)
Number of subjects: 8
Study 10367716 — intervention group
Group type: COMPARATOR
Intervention: Exercise-induced dehydration (E)
Number of subjects: 8
Study 10367716 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol hyperhydration (H)
Number of subjects: 8
Study 8607674 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Duraflo II)
Number of subjects: 20
Study 8607674 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuits
Number of subjects: 20
Study 1833245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 800 micrograms/d
Number of subjects: 16
Study 1833245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin 400 micrograms/d
Number of subjects: 16
Study 1833245 — intervention group
Group type: COMPARATOR
Intervention: Danazol 800 mg/d
Number of subjects: 16
Study 7139067 — intervention group
Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine in hard gelatin capsule
Number of subjects: 0
Study 7139067 — intervention group
Group type: COMPARATOR
Intervention: S-carboxymethylcysteine syrup
Number of subjects: 0
Study 30088162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen plus thoracic epidural analgesia (TEA)
Number of subjects: 120
Study 30088162 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA) alone
Number of subjects: 120
Study 28946075 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived benefit from condom use
Number of subjects: 0
Study 28946075 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived cost of condom use
Number of subjects: 0
Study 28946075 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 0
Study 28946075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cusp model
Number of subjects: 0
Study 25654431 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 77576
Study 24306437 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution (HR) practice when walking
Number of subjects: 0
Study 24306437 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-resolution (LR) practice when walking
Number of subjects: 0
Study 24306437 — intervention group
Group type: COMPARATOR
Intervention: High-resolution (HR) practice when using a wheelchair
Number of subjects: 0
Study 24306437 — intervention group
Group type: COMPARATOR
Intervention: Low-resolution (LR) practice when using a wheelchair
Number of subjects: 0
Study 22553919 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plasters on bilateral HT 7 acupoints
Number of subjects: 50
Study 22553919 — intervention group
Group type: COMPARATOR
Intervention: Inactive plasters (sham)
Number of subjects: 50
Study 19129989 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 15 mg/kg/dose (n=112)
Number of subjects: 301
Study 19129989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg/kg/dose (n=105)
Number of subjects: 301
Study 19129989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg/dose (n=84)
Number of subjects: 301
Study 18028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation syndrome (PEX)
Number of subjects: 1045
Study 18028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 50-59 years
Number of subjects: 1045
Study 18028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group > or = 80 years
Number of subjects: 1045
Study 18028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1045
Study 18028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1045
Study 18028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with PEX
Number of subjects: 1045
Study 18028119 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness, anterior chamber depth, lens thickness, nuclear lens opacifications, optic disc morphology
Number of subjects: 1045
Study 15385923 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) given as adjunct to chemotherapy (ATRA-arm, n=122)
Number of subjects: 242
Study 15385923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy (n=31)
Number of subjects: 242
Study 15385923 — intervention group
Group type: COMPARATOR
Intervention: No ATRA (standard-arm, n=120)
Number of subjects: 242
Study 11125238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine 40 mg
Number of subjects: 24
Study 11125238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11806464 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 or 8 mg once daily)
Number of subjects: 46
Study 11806464 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (20 or 40 mg once daily)
Number of subjects: 46
Study 9060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 74) - clinicians were strongly requested not to hospitalize for suspected IUGR if the Doppler findings were normal
Number of subjects: 150
Study 9060122 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 76) - standard management for suspected IUGR without revealing Doppler results
Number of subjects: 150
Study 9060122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 7822984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (200 mg of oral vitamin E for 4-8 weeks)
Number of subjects: 65
Study 7822984 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 65
Study 7822984 — intervention group
Group type: COMPARATOR
Intervention: Thalassemic patients (compared to 16 normal controls)
Number of subjects: 65
Study 7822984 — intervention group
Group type: COMPARATOR
Intervention: Thalassemic patients (Hb H disease)
Number of subjects: 65
Study 7822984 — intervention group
Group type: COMPARATOR
Intervention: Thalassemic patients (Hb H disease and beta‐thal/Hb E)
Number of subjects: 65
Study 2869648 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 53
Study 2869648 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 53
Study 2869648 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg labetalol
Number of subjects: 53
Study 2869648 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 53
Study 31672420 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Number of subjects: 20
Study 31672420 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study 29248384 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine + Hydrochlorothiazide (TAH) 40/5 mg + 12.5 mg
Number of subjects: 310
Study 29248384 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan/Amlodipine (TA) 40/5 mg
Number of subjects: 310
Study 29248384 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine + Hydrochlorothiazide (TAH)
Number of subjects: 310
Study 29248384 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan/Amlodipine (TA)
Number of subjects: 310
Study 27640138 — intervention group
Group type: EXPERIMENTAL
Intervention: High neutrophil-to-lymphocyte ratio (NLR) ≥3.0
Number of subjects: 393
Study 24670273 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocanalicular silicone intubation (MCI)
Number of subjects: 38
Study 24670273 — intervention group
Group type: COMPARATOR
Intervention: Bicanalicular silicone intubation (BCI)
Number of subjects: 38
Study 22907229 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 14
Study 20135214 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Love Workshop (HLW)
Number of subjects: 313
Study 20135214 — intervention group
Group type: COMPARATOR
Intervention: Comparison workshop
Number of subjects: 313
Study 18769354 — intervention group
Group type: COMPARATOR
Intervention: EVG/r alone (200/100 mg once daily)
Number of subjects: 0
Study 18769354 — intervention group
Group type: EXPERIMENTAL
Intervention: EVG added to TPV/r (500/200 mg twice daily)
Number of subjects: 0
Study 18769354 — intervention group
Group type: EXPERIMENTAL
Intervention: EVG added to DRV/r (600/100 mg twice daily)
Number of subjects: 0
Study 18769354 — intervention group
Group type: EXPERIMENTAL
Intervention: EVG/r (200/100 mg once daily)
Number of subjects: 0
Study 18769354 — intervention group
Group type: COMPARATOR
Intervention: EVG/r (125/100 mg once daily)
Number of subjects: 0
Study 16145283 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E emulsion
Number of subjects: 10
Study 16145283 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 10
Study 12020337 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/d of alcohol for 8 weeks
Number of subjects: 63
Study 12020337 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/d of alcohol for 8 weeks
Number of subjects: 63
Study 12020337 — intervention group
Group type: COMPARATOR
Intervention: 0 g/d of alcohol for 8 weeks
Number of subjects: 63
Study 10519499 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sided informed consent
Number of subjects: 770